Management of de-novo urothelial carcinoma in transplanted patients.
Journal
Current opinion in urology
ISSN: 1473-6586
Titre abrégé: Curr Opin Urol
Pays: United States
ID NLM: 9200621
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
entrez:
3
4
2020
pubmed:
3
4
2020
medline:
15
12
2020
Statut:
ppublish
Résumé
The aim of this article is to review incidence, risk factors, and optimal management of de-novo urothelial carcinoma in transplant recipients. There is a two to three-fold increased risk for de-novo malignant tumors after solid-organ transplantation, but there is currently no consensus regarding optimal management of de-novo urothelial carcinoma in transplanted patients. Known risk factors include polyomavirus BK, aristolochic acid, and smoking. Data suggest a higher rate of high-grade tumors, as well as predominantly higher stage at primary diagnosis, for both NMIBC and muscle-invasive bladder cancer (MIBC). Treatment for NMIBC includes TURB, mitomycin, and Bacille de Calmette-Guérin instillation with special concern to the immunosuppressive regime. Treatment of MIBC or advanced urothelial carcinoma includes radical cystectomy with chemotherapy if the patient is eligible. A screening should be performed in all transplant recipients, to allow early diagnosis. De-novo urothelial carcinoma in transplant recipients is more frequent than in the general population and these tumors were more likely to be high-grade tumors and diagnosed at an advanced stage. There is very little information available on the optimal treatment for these patients. However, aggressive treatment and a strict management according the given recommendations are of the utmost importance.
Identifiants
pubmed: 32235285
doi: 10.1097/MOU.0000000000000749
pii: 00042307-202005000-00028
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
467-474Références
Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125:1747–1754.
Engels EA, Pfeiffer RM, Fraumeni JF, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306:1891–1901.
Rossetto A, Tulissi P, De Marchi F, et al. De novo solid tumors after kidney transplantation: is it time for a patient-tailored risk assessment? Experience from a single center. Transplant Proc 2015; 47:2116–2120.
Hevia V, Gómez V, Díez Nicolás V, et al. Development of urologic de novo malignancies after renal transplantation. Transplant Proc 2014; 46:170–175.
Yan L, Salama ME, Lanciault C, et al. Polyomavirus large T antigen is prevalent in urothelial carcinoma post-kidney transplant. Hum Pathol 2016; 48:122–131.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet Lond Engl 2007; 370:59–67.
Rogers R, Gohh R, Noska A. Urothelial cell carcinoma after BK polyomavirus infection in kidney transplant recipients: a cohort study of veterans. Transpl Infect Dis 2017; 19:e12752.
Tomaszewski JJ, Larson JA, Smaldone MC, et al. Management of bladder cancer following solid organ transplantation. Adv Urol 2011; 2011:256985.
Lee KF, Tsai YT, Lin CY, et al. Cancer incidence among heart, kidney, and liver transplant recipients in Taiwan. PLoS One 2016; 11:e0155602.
Antunes H, Tavares-da-Silva E, Oliveira R, et al. De novo urologic malignancies in renal transplant recipients. Transplant Proc 2018; 50:1348–1354.
di Capua Sacoto C, Lujan Marco S, Bahilo Mateu P, et al. De novo urological neoplasms in kidney transplant patients: experience in 1,751 patients. Actas Urol Esp 2010; 34:88–94.
Thon WF, Kliem V, Truss MC, et al. Denovo urothelial carcinoma of the upper and lower urinary tract in kidney: transplant patients with end-stage analgesic nephropathy. World J Urol 1995; 13:254–261.
Ondruš D, Pribylincová V, Breza J, et al. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy. Int Urol Nephrol 1999; 31:417–422.
Chiang YJ, Chu SH, Liu KL, et al. Silent urothelial cancer detected by sonography after renal transplantation. Transplant Proc 2006; 38:2084–2085.
Ardelt PU, Rieken M, Ebbing J, et al. Urothelial cancer in renal transplant recipients: incidence, risk factors, and oncological outcome. Urology 2016; 88:104–109.
Cox J, Colli JL. Urothelial cancers after renal transplantation. Int Urol Nephrol 2011; 43:681–686.
Tsaur I, Karalis A, Blaheta R, et al. Transitional cell carcinoma of the native urinary tract after kidney transplantation: recommendations following a long-term retrospective analysis. Am J Med Sci 2011; 341:478–483.
Melchior S, Franzaring L, Shardan A, et al. Urological de novo malignancy after kidney transplantation: a case for the urologist. J Urol 2011; 185:428–432.
Palazzetti A, Bosio A, Dalmasso E, et al. De novo bladder urothelial neoplasm in renal transplant recipients: a retrospective, multicentered study. Urol Int 2018; 100:185–192.
Yu J, Lee CU, Kang M, et al. Incidences and oncological outcomes of urothelial carcinoma in kidney transplant recipients. Cancer Manage Res 2019; 11:157–166.
Medani S, O’Kelly P, O’Brien KM, et al. Bladder cancer in renal allograft recipients: risk factors and outcomes. Transplant Proc 2014; 46:3466–3473.
Karczewski M, Czapiewski W, Karczewski J. Urologic de novo malignancies after kidney transplantation: a single center experience. Transplant Proc 2012; 44:1293–1297.
Stolt A, Sasnauskas K, Koskela P, et al. Seroepidemiology of the human polyomaviruses. J Gen Virol 2003; 84:1499–1504.
Gupta G, Kuppachi S, Kalil RS, et al. Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant 2018; 18:245–252.
Liu S, Chaudhry M, Berrebi A, et al. Polyomavirus replication and smoking are independent risk factors for bladder cancer after renal transplantation. Transplantation 2017; 101:1488–1494.
Cai T, Mazzoli S, Meacci F, et al. Human papillomavirus and nonmuscle invasive urothelial bladder cancer: potential relationship from a pilot study. Oncol Rep 2011; 25:485–489.
Li N, Yang L, Zhang Y, et al. Human papillomavirus infection and bladder cancer risk: a meta-analysis. J Infect Dis 2011; 204:217–223.
Moonen PM, Bakkers JM, Kiemeney LA, et al. Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer. Eur Urol 2007; 52:464–468.
Polesel J, Gheit T, Talamini R, et al. Urinary human polyomavirus and papillomavirus infection and bladder cancer risk. Br J Cancer 2012; 106:222–226.
Lu QL, Lalani el-N, Abel P. Human papillomavirus 16 and 18 infection is absent in urinary bladder carcinomas. Eur Urol 1997; 31:428–432.
Xiao J, Zhu X, Hao GY, et al. Association between urothelial carcinoma after renal transplantation and infection by human papillomavirus types 16 and 18. Transplant Proc 2011; 43:1638–1640.
Swindle F, Rigby P, Hawley N. Transitional cell carcinoma in renal transplant recipients: the influence of compound analgesics. Br J Urol 1998; 81:229–233.
Roumeguère T, Broeders N, Jayaswal A, et al. Bacillus Calmette-Guerin therapy in nonmuscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int 2015; 28:199–205.
Tsai HL, Chang JW, Wu TH, et al. Outcomes of kidney transplant tourism and risk factors for de novo urothelial carcinoma. Transplantation 2014; 98:79–87.
Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000; 342:1686–1692.
Ehdaie B, Stukenborg GJ, Theodorescu D. Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer. J Urol 2009; 182:1482–1487.
Miao Y, Everly JJ, Gross TG, et al. De novo cancers arising in organ transplant recipients are associated with adverse outcomes compared with the general population. Transplantation 2009; 87:1347–1359.
Shiels MS, Copeland G, Goodman MT, et al. Cancer stage at diagnosis in patients infected with the human immunodeficiency virus and transplant recipients. Cancer 2015; 121:2063–2071.
Neuzillet Y, Cabaniols L, Karam G, et al. Study of urothelial bladder tumours in renal transplant recipients. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 2006; 16:343–346.
Elkentaoui H, Robert G, Pasticier G, et al. Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux. Urology 2010; 75:126–132.
Deresiewicz RL, Stone RM, Aster JC. Fatal disseminated mycobacterial infection following intravesical bacillus Calmette-Guerin. J Urol 1990; 144:1331–1333. discussion 1333–1334.
Yossepowitch O, Eggener SE, Bochner BH, et al. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. J Urol 2006; 176:482–485.
Wang HB, Hsieh HH, Chen YT, et al. The outcome of posttransplant transitional cell carcinoma in 10 renal transplant recipients. Clin Transplant 2002; 16:410–413.
Palou J, Angerri O, Segarra J, et al. Intravesical bacillus Calmette-Guèrin for the treatment of superficial bladder cancer in renal transplant patients. Transplantation 2003; 76:1514–1516.
Kamal MM, Soliman SM, Shokeir AA, et al. Bladder carcinoma among live-donor renal transplant recipients: a single-centre experience and a review of the literature. BJU Int 2008; 101:30–35.
Roumeguère T, Broeders N, Jayaswal A, et al. Bacillus Calmette-Guerin therapy in nonmuscle-invasive bladder carcinoma after renal transplantation for end-stage aristolochic acid nephropathy. Transpl Int Off J Eur Soc Organ Transplant 2015; 28:199–205.
Swietek N, Waldert M, Susani M, et al. Intravesical bacillus Calmette-Guérin instillation therapy for nonmuscle-invasive bladder cancer following solid organ transplantation. Wien Klin Wochenschr 2013; 125:189–195.
Rodriguez Faba O, Palou J, Vila Reyes H, et al. Treatment options and predictive factors for recurrence and cancer-specific mortality in bladder cancer after renal transplantation: a multiinstitutional analysis. Actas Urol Esp 2017; 41:639–645.
Neuzillet Y, Davin JL, Lechevallier E. [Intravesical BCG instillations for the treatment of superficial bladder tumours in renal transplant recipients]. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 2006; 16:32–35.
Tomaszewski JJ, Larson JA, Smaldone MC, et al. Management of bladder cancer following solid organ transplantation. Adv Urol 2011; 2011:256985.
Vegt PD, van der Meijden AP, Sylvester R, et al. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer Protocol 30911. J Urol 1997; 157:1246–1249.
Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK. BCG intravesical instillations: recommendations for side-effects management. Eur Urol 2000; 37: (Suppl 1): 33–36.
Durek C, Rüsch-Gerdes S, Jocham D, Böhle A. Interference of modern antibacterials with bacillus Calmette-Guerin viability. J Urol 1999; 162:1959–1962.
Wallerand H, Ravaud A, Ferrière JM. Bladder cancer in patients after organ transplantation. Curr Opin Urol 2010; 20:432–436.
Gunelli R, Bercovich E, Nanni O, et al. Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study. Br J Cancer 2007; 97:1499–1504.
Kao YL, Ou YC, Yang CR, et al. Transitional cell carcinoma in renal transplant recipients. World J Surg 2003; 27:912–916.
Diller R, Gruber A, Wolters H, et al. Therapy and prognosis of tumors of the genitourinary tract after kidney transplantation. Transplant Proc 2005; 37:2089–2092.
Manassero F, Di Paola G, Mogorovich A, et al. Orthotopic bladder substitute in renal transplant recipients: experience with Studer technique and literature review. Transpl Int Off J Eur Soc Organ Transplant 2011; 24:943–948.
Lang H, de Petriconi R, Wenderoth U, et al. Orthotopic ileal neobladder reconstruction in patients with bladder cancer following renal transplantation. J Urol 2005; 173:881–884.
Master VA, Meng MV, Grossfeld GD, et al. Treatment and outcome of invasive bladder cancer in patients after renal transplantation. J Urol 2004; 171:1085–1088.
Aldhaam NA, Elsayed AS, Jing Z, et al. Neoadjuvant chemotherapy is not associated with adverse perioperative outcomes after robot-assisted radical cystectomy: a case for increased use from the IRCC. J Urol 2020; 203:57–61.
Atallah A, Rady MR, Kamal HM, et al. Telovelar approach to pediatric fourth ventricle tumors: feasibility and outcome. Turk Neurosurg 2019; 29:497–505.
Tillou X, Raynal G, Limani K, et al. Carcinoma in situ in bladder and urethra among renal transplanted patient: failure of BCG therapy. Prog Urol 2008; 18:1097–1099.
Olsburgh J, Zakri RH, Horsfield C, et al. TCC in transplant ureter: when and when not to preserve the transplant kidney. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2016; 16:704–711.
Boissier R, Hevia V, Bruins HM, et al. The risk of tumour recurrence in patients undergoing renal transplantation for end-stage renal disease after previous treatment for a urological cancer: a systematic review. Eur Urol 2018; 73:94–108.
Gifford RR, Wofford JE, Edwards WG. Carcinoma of the bladder in renal transplant patients: a case report and collective review of cases. Clin Transplant 1998; 12:65–69.
Yossepowitch O, Sagy I, Margel D, Baniel J. Urothelial carcinoma of the bladder in patients on hemodialysis: clinical characteristics and oncological outcomes. J Urol 2012; 187:1215–1219.
Strecker T, Rösch J, Weyand M, Agaimy A. Frequency and spectrum of metachronous malignancies in heart transplant recipients: a 11-year-experience at a German heart center. Int J Clin Exp Pathol 2013; 6:411–420.
von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol Off J Am Soc Clin Oncol 2000; 18:3068–3077.
Witjes JA, Bruins M, Cathomas R, et al. Muscle-invasive and Metastatic Bladder Cancer. Online. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands, 2019.
Matzkies FK, Tombach B, Dietrich M, et al. MVAC-therapy for advanced urothelial carcinoma in an anuric renal transplant recipient. Nephrol Dial Transplant 2000; 15:110–112.
Benisovich VI, Silverman L, Slifkin R, et al. Cisplatin-based chemotherapy in renal transplant recipients: a case report and a review of the literature. Cancer 1996; 77:160–163.
Bordi P, Tiseo M, Baldari G, Buti S. Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report. BMC Cancer 2016; 16:626.
Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. J Immunother Hagerstown Md 19972017; 40:277–281.
Regalla DK, Williams GR, Paluri RK. Immune checkpoint inhibitors in the management of malignancies in transplant recipients. Postgrad Med J 2018; 94:704–708.
Lai HC, Lin JF, Hwang TI, et al. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? Int J Mol Sci 2019; 20:
Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer 2019; 7:106.
Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review. J Am Acad Dermatol 2020.
Wu CK, Juang GD, Lai HC. Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration. Ann Oncol 2017; 28:2895–2896.
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work GroupKDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg 2009; 9: (Suppl 3): S1–S155.
Kleinclauss F, Thuret R, Murez T, Timsit MO. [Urologic malignancies in renal transplant candidates and recipients]. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 2016; 26:1094–1113.
Reichelt O, Wunderlich H, Neiser G, Schubert J. How reliable is conventional urinary cytology in posttransplant patients? Urol Int 2003; 71:176–177.
Bhatnagar R, Drachenberg C, Staats PN. Renal tubular epithelial clusters in voided urine: a potential diagnostic pitfall in renal transplant patients. J Am Soc Cytopathol 2014; 3:96–102.
Breda A, Budde K, Figueiredo A, et al. Renal Transplantation. Online. ISBN 978-94-92671-04-2. EAU Guidelines Office, Arnhem, The Netherlands, 2019.